Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679263 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
A Phase 2 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00679263: Completed Phase 2 study, sponsored by MediciNova.
NCT00679263 is a Phase 2 study that has completed, run by MediciNova. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679263, a Phase 2 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
Interventions
- DRUG Placebo
- DRUG MN-221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00679263 record still lists
NCT00679263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00679263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00679263 about?
NCT00679263 is a clinical study titled "Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma". The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
What is the current status of trial NCT00679263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00679263?
The interventions under investigation include: Placebo (DRUG), MN-221 (DRUG).
Who is sponsoring clinical trial NCT00679263?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00679263's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia